Evidence map›Paper›PMID 42111070›Full record

ReviewFrontiers in neurology

Microbiota and Guillain-Barré syndrome: role of microbial metabolites, biomarkers, and emerging therapeutic strategies.

María Zurdo-López, Miriam Sagredo Del Rio, Matilde Cháfer Rudilla, Antonio Ibarra, Ernesto Doncel-Pérez

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in neurology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

María Zurdo-LópezLaboratorio de Bioquímica Clínica, Hospital General Universitario de Toledo, Servicio de Salud de Castilla-La Mancha (SESCAM), Toledo, Spain.
Miriam Sagredo Del RioLaboratorio de Bioquímica Clínica, Hospital General Universitario de Toledo, Servicio de Salud de Castilla-La Mancha (SESCAM), Toledo, Spain.
Matilde Cháfer RudillaLaboratorio de Bioquímica Clínica, Hospital General Universitario de Toledo, Servicio de Salud de Castilla-La Mancha (SESCAM), Toledo, Spain.
Antonio IbarraCentro de Investigación en Ciencias de la Salud (CICSA), Facultad de Ciencias de la Salud, Campus Norte de la Universidad Anáhuac, Huixquilucan, Estado de México, Mexico.
Ernesto Doncel-PérezCentro de Investigación en Ciencias de la Salud (CICSA), Facultad de Ciencias de la Salud, Campus Norte de la Universidad Anáhuac, Huixquilucan, Estado de México, Mexico.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Guillain-Barré syndrome (GBS) is an acute autoimmune polyradiculoneuropathy that follows infection and is characterized by immune-mediated demyelination or axonal injury of the peripheral nervous system. While established triggers such as

Indexed as

biomarkersGuillain–Barré syndromegut microbiotamicrobial metabolitesneuroprotectionshort-chain fatty acids

Identifiers

PMID42111070
PMCPMC13149125

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.